Preconception Optimization, Risk Stratification
and Medication Reconciliation
Defined by anti-U1RNP antibodies with overlapping features of SLE, SSc, and PM/DM.
Pulmonary arterial hypertension, interstitial lung disease, and renal involvement.
Live-birth rate ~72% with meticulous preconception evaluation.
Determine if the patient's physical reserve can tolerate the hemodynamic shifts of pregnancy without triggering disease flares or severe morbidity.
Baseline echocardiogram and pulmonary function tests before authorizing conception.
Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are primary concerns.
Severe PAH is an absolute contraindication to pregnancy due to extreme maternal mortality risk.
Establish baseline renal function before conception.
Estimated glomerular filtration rate to quantify renal reserve.
Spot urine protein-to-creatinine ratio to detect subclinical nephritis.
Active nephritis or baseline renal insufficiency strongly predicts superimposed preeclampsia and irreversible maternal renal decline.
Overlapping autoantibody profiles dictate specific obstetrical surveillance protocols. Test all patients preconception.
Increased risk of early pregnancy loss via placental thrombosis.
Placental insufficiency secondary to antiphospholipid-mediated vasculopathy.
Severe, early-onset preeclampsia with risk of maternal end-organ damage.
aPL-positive patients require prophylactic or therapeutic LMWH and low-dose aspirin upon conception.
| Medication | Status | Action / Recommendation |
|---|---|---|
| Hydroxychloroquine (HCQ) | Safe | Continue throughout pregnancy; reduces flare frequency |
| Azathioprine | Safe | Maintain as steroid-sparing agent (≤2 mg/kg/day) |
| Calcineurin Inhibitors | Safe | Monitor maternal BP and renal function closely |
| Low-dose Corticosteroids | Safe | Prednisone ≤10 mg/day; lowest effective dose |
| Methotrexate | Contraindicated | Discontinue 1–3 months prior to conception |
| Mycophenolate Mofetil | Contraindicated | Discontinue ≥6 weeks prior; embryopathy risk |
| Cyclophosphamide | Contraindicated | Avoid; severe teratogenicity and gonadal toxicity |
MCTD profoundly increases the risk of preeclampsia via defective spiral artery remodeling.
Placental insufficiency demands rigorous third-trimester surveillance for FGR and preterm birth.
Postpartum flares are common due to precipitous drops in endogenous corticosteroids. A preemptive postpartum medication escalation plan is required.
6 months continuous remission on pregnancy-safe medications before conception.
Echo + PFTs. Rule out PAH — absolute contraindication to pregnancy.
Creatinine, eGFR, spot urine protein : creatinine ratio.
aPL panel (LAC, aCL, anti-β2GPI) and anti-Ro/SSA, anti-La/SSB.
Discontinue MTX, MMF, CYC well before stopping contraception.
Establish MFM, Rheumatology, and Pulm/Neph co-management plan.